Median plasma and skin concentrations of miltefosine on days 28 and 42, of paromomycin on day 14, and liposomal amphotericin B on day 7.
(A) Median plasma and skin concentration of miltefosine on day 28 (arm 2) were 28.5 μg/ml and 49 μg/g, respectively, with median skin to plasma concentration ratio calculated at 1.64 (IQR = 0.62–4.35); (B) Median plasma and skin concentration of miltefosine on day 42 (arm 1) were 32.9 μg/ml and 46.7 μg/g, respectively, with median skin to plasma concentration ratio calculated at 1.46 (IQR = 0.57–3.23); (C) Median plasma and skin concentration of paromomycin on day 14 (arm 1, intensive PK cohort) were 40.5 μg/ml and 17.3 μg/g, respectively, with median skin to plasma concentration ratio calculated at 0.44 (IQR = 0.2–1.05); (D) Median plasma and skin concentration of LAmB on day 7 (arm 2) were 55.8 μg/ml and 7.63 μg/g, respectively, with median skin to plasma concentration ratio calculated at 0.11 (IQR = 0.02–0.94).